MSP Recovery Approved Amidst Market Bloodbath

by BA Research | May 18, 2022

LCAP gets approval for MSP Recovery. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

SPAC Deal: THCA Tuscan Holdings Corp. II + Surf Air Mobility

Tuscan Holdings Corp. II (THCA) announces DA with Surf Air Mobility. The transaction values Surf Air Mobility at an enterprise value of $1.42B. No PIPE. Surf Air Mobility is a regional air mobility platform with scheduled routes and on demand charter flights operated by third-party Part 135 charter operators. Slide deck here. THCA has had multiple extensions and 84% redemptions already– deadline was end of June.

LCAP Approves MSP Recovery

Lionheart Acquisition Corporation II (LCAP) approve its merger with MSP Recovery (MSPR). The transaction is expected to close on 5/20 .

DWAC / Truth Social launches Mobile App

Digital World Acquisition Corp (DWAC) / Trump Media & Technology Group, the parent company of Truth Social, announced the launch of the Truth Social Web App, which allows users to access Truth Social from any Internet-connected computer, phone, or device. DWAC shares are down 14% YTD.

Elsewhere in SPACs

North Atlantic Acquisition Corporation (NAAC) – vote pushed to 6/1
Kingswood Acquisition Corp (KWAC) – approved to November

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Weekly Boardroom & Executive Moves: May 1, 2026

This week, significant leadership changes occurred across several companies facing financial difficulties. Abbott Laboratories (ABT) and Agilon Health Inc (AGL) appointed new board members and executives amidst high activist risks and declining TSRs. Accuray Inc (ARAY) and ALT5 Sigma Corp (ALTS) also saw key executive departures and appointments as they navigate substantial TSR declines. These shifts highlight the ongoing challenges and strategic redirections needed to stabilize operations and improve shareholder value.

Daily SPAC Update – May 1, 2026

Two SPAC IPOs launched today, raising a total of $500 million. CH4 Natural Solutions Acquisition Corp (MTNE) secured $300 million, while Quantum Leap Acquisition Corp (QLEP) raised $200 million. Today, 2 SPAC IPOs raised $500M, led by CH4 Natural Solutions (MTNE) at $300M. This follows a surge of activity at the end of April.

Daily SPAC Update – April 30, 2026

Today, six SPACs debuted, raising a total of $965 million. General Catalyst Global Resilience Merger Corp (GCGR) led the pack with $350 million, followed by RRE Ventures Acquisition Corp. (RREV) at $250 million. Month-to-date, SPAC IPOs total 16, bringing in $2.65 billion, compared to 11 IPOs last month that raised $1.72 billion.

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Daily SPAC Update – April 28, 2026

SPAC IPOs Look Stalled Again as Irenic’s $220M IPO Only Makes it Seven. Miluna Acquisition + CADV.AI Deal. Prophyte Extension Vote to Add 12 More Months.

Subscribe to Boardroom Alpha Newsletters

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.